Hier M P, Black M J, Shenouda G, Sadeghi N, Karp S E
Department of Otolaryngology, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada.
Laryngoscope. 1995 Oct;105(10):1077-80. doi: 10.1288/00005537-199510000-00013.
A murine model for the immunotherapy of head and neck cancer was established. The AT-84 tumor, a spontaneously arising oral squamous cell tumor of C3H mice, was evaluated for susceptibility to lymphokine-activated killer (LAK) cells. In vitro chromium-release assays demonstrated that AT-84 is sensitive to LAK-cell-mediated killing. Furthermore, in vivo experiments employing a lung metastasis model demonstrated a 50% reduction in the number of metastases in LAK-cell-treated mice as compared with untreated controls (P2 = .001). These experiments showed that AT-84 is an appropriate model for the immunotherapy of head and neck cancer. This model should be invaluable for further study of the mechanisms involved in immune-mediated therapy of head and neck cancer.
建立了一种用于头颈癌免疫治疗的小鼠模型。对AT - 84肿瘤（一种C3H小鼠自发产生的口腔鳞状细胞瘤）进行了对淋巴因子激活的杀伤细胞（LAK细胞）敏感性的评估。体外铬释放试验表明，AT - 84对LAK细胞介导的杀伤敏感。此外，采用肺转移模型的体内实验表明，与未治疗的对照组相比，接受LAK细胞治疗的小鼠转移灶数量减少了50%（P2 = 0.001）。这些实验表明，AT - 84是头颈癌免疫治疗的合适模型。该模型对于进一步研究头颈癌免疫介导治疗所涉及的机制应具有重要价值。
